These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 21936830)
1. SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions. Zani ML; Tanga A; Saidi A; Serrano H; Dallet-Choisy S; Baranger K; Moreau T Biochem Soc Trans; 2011 Oct; 39(5):1441-6. PubMed ID: 21936830 [TBL] [Abstract][Full Text] [Related]
2. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Moreau T; Baranger K; Dadé S; Dallet-Choisy S; Guyot N; Zani ML Biochimie; 2008 Feb; 90(2):284-95. PubMed ID: 17964057 [TBL] [Abstract][Full Text] [Related]
3. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases. Zani ML; Baranger K; Guyot N; Dallet-Choisy S; Moreau T Protein Sci; 2009 Mar; 18(3):579-94. PubMed ID: 19241385 [TBL] [Abstract][Full Text] [Related]
4. Secretory leukocyte protease inhibitor (SLPI) is, like its homologue trappin-2 (pre-elafin), a transglutaminase substrate. Baranger K; Zani ML; Labas V; Dallet-Choisy S; Moreau T PLoS One; 2011; 6(6):e20976. PubMed ID: 21687692 [TBL] [Abstract][Full Text] [Related]
5. Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Guyot N; Zani ML; Maurel MC; Dallet-Choisy S; Moreau T Biochemistry; 2005 Nov; 44(47):15610-8. PubMed ID: 16300411 [TBL] [Abstract][Full Text] [Related]
6. The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function. Baranger K; Zani ML; Chandenier J; Dallet-Choisy S; Moreau T FEBS J; 2008 May; 275(9):2008-20. PubMed ID: 18341586 [TBL] [Abstract][Full Text] [Related]
7. Protection of lung epithelial cells from protease-mediated injury by trappin-2 A62L, an engineered inhibitor of neutrophil serine proteases. Tanga A; Saidi A; Jourdan ML; Dallet-Choisy S; Zani ML; Moreau T Biochem Pharmacol; 2012 Jun; 83(12):1663-73. PubMed ID: 22465040 [TBL] [Abstract][Full Text] [Related]
8. Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. van Wetering S; van der Linden AC; van Sterkenburg MA; Rabe KF; Schalkwijk J; Hiemstra PS J Investig Med; 2000 Sep; 48(5):359-66. PubMed ID: 10979241 [TBL] [Abstract][Full Text] [Related]
9. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. Schmid M; Fellermann K; Fritz P; Wiedow O; Stange EF; Wehkamp J J Leukoc Biol; 2007 Apr; 81(4):907-15. PubMed ID: 17200145 [TBL] [Abstract][Full Text] [Related]
10. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Sallenave JM; Shulmann J; Crossley J; Jordana M; Gauldie J Am J Respir Cell Mol Biol; 1994 Dec; 11(6):733-41. PubMed ID: 7946401 [TBL] [Abstract][Full Text] [Related]
11. Periodontal pathogens affect the level of protease inhibitors in gingival crevicular fluid. Laugisch O; Schacht M; Guentsch A; Kantyka T; Sroka A; Stennicke HR; Pfister W; Sculean A; Potempa J; Eick S Mol Oral Microbiol; 2012 Feb; 27(1):45-56. PubMed ID: 22230465 [TBL] [Abstract][Full Text] [Related]
12. Kinetics of the inhibition of neutrophil proteinases by recombinant elafin and pre-elafin (trappin-2) expressed in Pichia pastoris. Zani ML; Nobar SM; Lacour SA; Lemoine S; Boudier C; Bieth JG; Moreau T Eur J Biochem; 2004 Jun; 271(12):2370-8. PubMed ID: 15182352 [TBL] [Abstract][Full Text] [Related]
13. SLPI and elafin: multifunctional antiproteases of the WFDC family. Scott A; Weldon S; Taggart CC Biochem Soc Trans; 2011 Oct; 39(5):1437-40. PubMed ID: 21936829 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of human elafin. Shaw L; Wiedow O Biochem Soc Trans; 2011 Oct; 39(5):1450-4. PubMed ID: 21936832 [TBL] [Abstract][Full Text] [Related]
15. Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): evidence for tryptase-mediated generation of elafin. Guyot N; Zani ML; Berger P; Dallet-Choisy S; Moreau T Biol Chem; 2005 Apr; 386(4):391-9. PubMed ID: 15899702 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of murine neutrophil serine proteinases by human and murine secretory leukocyte protease inhibitor. Wright CD; Kennedy JA; Zitnik RJ; Kashem MA Biochem Biophys Res Commun; 1999 Jan; 254(3):614-7. PubMed ID: 9920787 [TBL] [Abstract][Full Text] [Related]
17. Interaction of secretory leukocyte protease inhibitor with proteinase-3. Rao NV; Marshall BC; Gray BH; Hoidal JR Am J Respir Cell Mol Biol; 1993 Jun; 8(6):612-6. PubMed ID: 8100709 [TBL] [Abstract][Full Text] [Related]